Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.35 |
| ▸ | CTSS | P25774 | 6/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13680124 | 0.83 | GAA (0.41) | CA12CA2CA14 | |
| SCHEMBL13680122 | 0.78 | GAA (0.52) | — | |
| SCHEMBL6206868 | 0.76 | DGAT1 (0.39) | DGAT1CYP2D6CA12CA2CA14 | |
| SCHEMBL4085921 | 0.76 | LDHA (0.38) | CYP2D6 | |
| SCHEMBL241533 | 0.75 | DGAT1 (0.46) | DGAT1CYP2D6CA12CA2CA14 | |
| SCHEMBL13680145 | 0.74 | MGAM (0.33) | — | |
| Methyl Alcohol SCHEMBL27995686 | 0.73 | DGAT1 (0.44) | DGAT1CYP2D6CA12CA2CA14 | |
| SCHEMBL19216586 | 0.72 | DGAT1 (0.37) | DGAT1CYP2D6MTNR1AMTNR1BCA12 | |
| SCHEMBL9464796 | 0.72 | CA14 (0.38) | DGAT1CYP2D6CA12CA2CA14 | |
| SCHEMBL28508164 | 0.72 | MCL1 (0.39) | CTSKCTSSCTSLCTSBDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730803-B2 | PRODUCTION METHOD OF A BETA -KETO ESTER COMPOUND OF CLAIM 1, WHICH COMPRISES CONDENSATION OF A 2-CYANO-2,2-DIMETHYLACETATE SOLUTION TO GIVE 2-CYANO-2,2- DIMETHYLACETATE OF THE FORMULA (II), AND CONDENSATION THEREOF | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20030144533-A1 | Synthetic intermediate for epothilone derivative and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144533-A1 | Synthetic intermediate for epothilone derivative and production method thereof | HSD11B1, HSD17B7, HSD17B1 | CTSK 4265/4885CTSS 4706/4885CTSL 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.